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Vδ2+ T cells are a relatively well characterized lymphocyte subset, and are predominant among the
γδ T cell compartment in human peripheral blood. Known to increase post-natally as a proportion
of peripheral blood γδ T cells in early life (1, 2), they feature a dominant but not universal
Vγ9+ Vδ2+ usage (3), and mostly recognize low-molecular-weight pyrophosphate antigens (pAg),
which can be either derived from the host mevalonate pathway (isopentenyl pyrophosphate, IPP)
or microbially generated via the non-mevalonate pathway ((E)-4-Hydroxy-3-methyl-but-2-enyl
pyrophosphate, HMB-PP) (4). In addition, although recent work from our group provides some
evidence for selective maturation during life (5), it also clear that the Vδ2+ repertoire is dominated
both in neonates and adults by a semi-invariant Vγ9+ Vδ2+ TCR repertoire, including public
Vγ9 clonotypes, consistent with an innate-like paradigm involving pre-programmed recognition
of pAgs from birth (5, 6).
However, our recent data (5) suggest that in addition to pAg-reactive Vγ9+ Vδ2+ T cells,
the Vδ2+ T cell compartment harbors a distinct subset of Vγ9neg T cells, which adopt a
highly divergent immunobiology from their semi-invariant Vγ9+ colleagues. The existence
of Vγ9neg Vδ2+ T cells has been recognized for a number of years. Data from cord blood
indicated that the Vδ2 chain can associate with a variety of different chains other than Vγ9
(7). However, whether these cells generally persist into adulthood was unclear, as was their
role and significance. Some observations have hinted at both persistence and significance. In
a rare form of autoimmune polymyositis, highly clonal Vγ9neg Vδ2+ T cells were observed to
infiltrate into muscle and peri-muscular zones and destroy muscle fibers (8, 9). Furthermore,
a patient with Felty’s syndrome, which is characterized by leukopenia and splenomegaly in the
context of seropositive rheumatoid arthritis, was found to have an expanded population of Vγ9neg
Vδ2+ T cells in peripheral blood that was capable of producing TNFα in response to in vitro
CD3 stimulation (10). In addition, expanded Vγ9neg Vδ2+ T cell clonotypes were observed
in a single individual following stem cell transplantation (SCT), and a single healthy control
(11). Furthermore, a recent study noted the presence of Vδ2+ TCR clonotypes within TCR
repertoire analyses of the Vγ9neg compartment, and detected variable numbers of Vγ9neg Vδ2+
T cells by flow cytometry in healthy adults and chronic HCV patients (12). However, despite
these efforts, it was unclear if such Vγ9neg Vδ2+ T cells represented isolated clones in certain
individuals, or reflected a common and immunophenotypically and/or functionally distinct T cell
subset.
Now a recent study from our own laboratory establishes that Vγ9neg Vδ2+ T cells commonly
persist into adulthood, typically at low levels, and that they represent a previously unrecognized
adaptive T cell subset (Figure 1). The study provides both immunophenotypic and TCR
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FIGURE 1 | There are two subsets of Vδ2+ T cells in human peripheral blood. The predominant Vγ9+Vδ2+ subset is generated during gestation, expresses Vγ9
chains with public CDR3 sequences, and undergoes peripheral selection and polyclonal expansion during childhood to become pAg-reactive “innate-like” effector
cells (13). In contrast, Vγ9negVδ2+ T cells express Vδ2 paired with various Vγ chains bearing private CDR3 sequences, and these cells circulate in the peripheral
blood as naïve T cells until they encounter a specific antigenic challenge (which can include, but is likely not limited to, CMV infection). Antigen-specific Vγ9negVδ2+ T
cells undergo clonal expansion and differentiate into effector T cells, similar to Vδ1+ T cells. The antigens recognized by Vγ9negVδ2+ T cells remain unknown,
although bacterial and human aminoacyl-tRNA synthetases have been identified as candidate antigens for a single Vγ3+Vδ2+ T cell clone (14).
repertoire-based evidence strongly supporting an adaptive
biology, identifies a microbial stimulus the subset can respond
to, establishes they can access solid tissues (specifically the
liver), and also describes flow cytometry-based methods for their
routine detection (5). Vγ9neg Vδ2+ T cells typically adopted a
naïve phenotype in peripheral blood, accompanied by a diverse
and highly private TCR repertoire (including Vγ2-8 chains),
but occasionally displayed a differentiated, clonally expanded
Teffector phenotype. In addition, Vγ9
neg Vδ2+ TCRγ and TCRδ
CDR3 regions lacked motifs associated with pAg recognition,
and unlike Vγ9+ Vδ2+ T cells did not utilize JγP, instead
preferentially utilizing Jγ1/2 or JγP1. Consistent with these
observations and with reports that Vγ9+ Vδ2+ reactivity to pAg
is dependent upon both Vδ2 and Vγ9 chains (15), the Vγ9neg
Vδ2+ subset was not pAg reactive. These new findings suggested
a close parallel between the immunophenotypic features of
the Vγ9neg Vδ2+ subset and those of Vδ1+ T cells (16, 17),
and highlighted key differences with the Vγ9+ Vδ2+ T cell
subset.
What immune challenges might the Vγ9neg Vδ2+ subset
respond to? The apparently similar immunobiology of Vγ9neg
Vδ2+ and Vδ1+ T cells suggested viral infection as a likely
candidate, given that in response to CMV Vδ1+ T cells can
increase in number (18, 19), and undergo clonotypic expansion
(11), and that they may also respond to other viruses (20,
21). This was confirmed by the observation that after acute
CMV, Vγ9neg Vδ2+ T cells can transition from from a CD27hi
naïve-like phenotype to CD27lo/neg effector-like populations,
alongside clonal expansion (5). This finding extends previous
studies of Ravens (11) and Davey (16) by providing clear
confirmation that an individual microbial stimulus can not
only induce TCR clonotypic expansion but also concomitant
adaptive differentiation from Tnaive to Teffector status. Of strong
significance is the observation that, for both Vγ9neg Vδ2+ T
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cells and Vδ1+ T cells, this transition is marked by upregulation
effector/cytotoxic markers including Granzyme A, CD16, as
well as downregulation of lymphoid homing markers strongly
expressed on naïve populations such as CCR7, and upregulation
of the peripheral homing marker and chemokine receptor
CX3CR1 (5, 16). Also, the CDR3 sequences of clonotypically
expanded TCRs observed in different individuals were diverse,
as for Vδ1+ expansions, contrasting with the high level of Vγ9
TCRγ publicity observed within the Vγ9+ Vδ2+ T cell repertoire.
Another key feature of Vγ9+ Vδ2+ T cells, namely their
predominant peripheral blood localisation, was also compared
for Vγ9neg Vδ2+ T cells, in the context of human blood and
liver samples. Tellingly, whereas the Vδ2+ T cell compartment
as a whole was preferentially enriched in peripheral blood, the
Vγ9neg Vδ2+ subset was preferentially enriched in human liver
relative to peripheral blood. This result indicates that the Vγ9+
Vδ2+ and Vγ9neg Vδ2+ subsets are not only distinguished by
their TCR repertoire, immunophenotype, and responsiveness
to distinct microbial challenges, but also by their homing
properties, and further strengthens parallels with Vδ1+ T cells,
which share the ability to respond to CMV (11), and are
also preferentially enriched in solid tissues such as the liver
(22).
The Vδ2+ T cell compartment therefore includes both
innate-like and adaptive subsets, which have a very different
immunobiology to each other. In addition, the fact that Vγ9neg
Vδ2+ T cells appear to adopt a very similar overall biology
to Vδ1+ T cells (16, 17) is intriguing, and suggests the
existence of an adaptive γδ paradigm in humans that at least
these two distinct subsets (Vδ1+ and Vγ9neg Vδ2+ T cells)
appear to exhibit. Furthermore, the fact that both Vγ9neg Vδ2+
and Vδ1+ T cell expansions display an effector phenotype,
are relatively long-lived, and in the case of Vδ1+ T cells
display a far quicker response to TCR stimulation than their
naïve counterparts, suggests their potential to contribute to
immunoprotective effector memory responses following initial
pathogen exposure (5, 16, 17). Clearly many questions regarding
this paradigm are still unresolved—such as how clonal expansion
is initiated, about the underpinning transcriptional control
mechanisms, and also crucially regarding the nature of TCR
ligands that trigger such clonal expansions, both in blood and
solid tissues. However these recent studies establish clonotypes
and highlight clinical scenarios with which to answer these
questions.
Importantly, these recent findings establish the antibodies
required for reliable flow cytometry-based identification of this
new subset, thereby paving the way for investigation of Vγ9neg
Vδ2+ T cells in a wider range of peripheral tissues. Conceivably,
due to the inability of some Vδ2-specific mAbs to detect Vγ9neg
Vδ2+ T cells (5), the presence of this subset could have been
overlooked in some previous studies. Additionally, while Vγ9neg
Vδ2+ T cells clearly clonally expand in response to CMV, as
do Vδ1+ T cells, the full range of pathogens they respond to
is unclear, and the suspicion is that, as for Vδ1+ T cells, a
wider range of pathogens is likely to be relevant. Similarly, while
current studies have been restricted to studying the subset in
blood and the liver, there are likely to be additional tissues
in which Vγ9negVδ2 T cells are present and can mount such
responses.
These recent findings raise many questions regarding Vγ9neg
Vδ2+ T cells, such as why, given the evidence that the subset
responds to acute CMV within peripheral blood, do most
individuals chronically infected with CMV harbor peripheral
blood Vγ9neg Vδ2+ T cell populations that are naïve. Despite the
observation that Vγ9neg Vδ2+ T cell clonotypes can persist for 5
years (at least in immunosuppressed individuals), one possibility
is that the kinetics of their differentiation favor a limited duration
for Vγ9neg Vδ2+ T cell responses. Notably, the Vγ9neg Vδ2+
Teffector response can become increasingly focused on fewer TCR
clonotypes over that time period (5). It is therefore possible
that terminal differentiation and subsequent apoptosis focuses
and ultimately eliminates such Teffector responses, depending
on their duration since initial CMV infection. Another, not
mutually exclusive possibility, is that only a limited proportion
of individuals are able to respond to primary infection in the
first instance. This is consistent with our recent observations
in acute CMV infection, where one of three patients who
developed acute CMV did not appear to mount a Vγ9neg Vδ2+
T cell response (5), at least in peripheral blood. One caveat
is that recent work on hepatic Vδ1+ T cells has shown that
while some expanded clonotypes are present in both blood
and the liver, others are restricted to the liver and display a
distinct phenotype suggestive of hepatic residency (22). If this
same principle applies to the Vγ9neg Vδ2+ T cell subset, it is
conceivable that some individuals mount a response restricted
to peripheral tissue compartments but undetectable in blood. A
third, non-mutually exclusive possibility is that the emergence of
a Vγ9neg Vδ2+ T cell response, or lack thereof, is dependent on
contributions of other arms of the immune system, in keeping
with the idea that γδ T cell responses may be exacerbated
in clinical scenarios when conventional immune subsets are
suppressed. Whether the subset exclusively responds during
acute infection, or additionally during periods of reactivation,
is also unknown. However, of relevance, a single chronically
infected CMV+ healthy donor whose Vγ9neg Vδ2+ subset was
both clonally expanded and clearly displayed Teffector status was
suspected to have undergone recent CMV reactivation, based
on raised CMV-specific IgG levels, consistent with this latter
possibility (5).
In summary, several features of the Vγ9neg Vδ2+ T cell
subset are highly suggestive of an adaptive immunobiology,
which following a response can culminate in the generation of
a wave of Teffector cells that are relatively long lived, and appear
likely to provide an ongoing memory/effector contribution
to immunosurveillance, most likely to chronic/recurrent
infections. Ultimately this raises the intriguing possibility of
whether the subset could be harnessed immunotherapeutically
to enhance such protection, alongside other adaptive γδ T
cell subsets such as Vδ1+ T cells. However, like conventional
αβ adaptive immunity, the prospect that alongside protective
immunity the Vγ9neg Vδ2+ T cell subset could in some
instances contribute to autoimmune responses has already
been highlighted in the literature (8, 9). The recent study
by Davey et al. (5) outlined here provides an intellectual
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and methodological basis from which to investigate the
role of this intriguing new subset more fully, in both
pathogen-specific immunity and immunopathological
responses in different compartments of the human immune
system.
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